Global Med Technologies(R) Receives FDA 510(k) Clearance for ElDorado Donor Doc(TM)
June 04 2007 - 10:00AM
PR Newswire (US)
Wyndgate(R) Technologies Introduces Its New ElDorado(TM) Donor Doc
Product, Cleared for Marketing in the U.S. DENVER, Colo., June 4
/PRNewswire-FirstCall/ -- Wyndgate Technologies(R), a division of
Global Med Technologies(R), Inc. (OTC:GLOB) (BULLETIN BOARD: GLOB)
, today announced that the U.S. Food and Drug Administration (FDA)
has granted 510(k) clearance for Donor Doc(TM), paving the way for
the Company to proceed to market the product in the United States.
( LOGO: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
) The Donor Doc release introduces Wyndgate's new ElDorado suite of
integrated blood management solutions and shares key component
modules with future products. Donor Doc is the Company's
next-generation software which creates a bridge between Wyndgate's
popular SafeTrace(R) systems and its donor and transfusion software
innovations which are nearing completion. ElDorado Donor Doc is an
electronic health history questionnaire and physical exam tracking
system which assists blood centers in screening donors by capturing
medical and physical examination information. The system allows
donors to self-administer questionnaires at an individual's pace,
choosing text or audio presentation of questions in their preferred
language, as well as graphics to clarify content. Donor Doc may be
implemented on standard and touch-screen computers allowing maximum
flexibility at fixed-site and mobile blood drives. The software
identifies donor responses where additional staff investigation is
necessary and helps blood centers prevent release of products from
unsuitable donors. Donor Doc also provides maximum integration with
donor center information systems, including SafeTrace, the
Company's blood center management system. To assure that Donor Doc
would meet client demands for features and performance, Wyndgate
organized a technology work group consisting of leading industry
representatives from around the world. The group provided guidance
during analysis, development and beta testing of Donor Doc, and
their contributions assisted the Company in delivering a
feature-rich and user friendly solution. The resulting software
system streamlines the experience for donors and staff and helps
customers to realize efficiencies and cost savings, while improving
overall safety. Thomas F. Marcinek, President and Chief Operating
Officer, commented, "We are excited that we can accept orders from
customers in the U.S. for this potentially high-demand product now
that it has been 510(k) cleared. The Company has made a serious
commitment to our customers by continuing to invest in innovations
which help them meet their business and regulatory needs." Mr.
Marcinek further commented, "Global Med is dedicated to providing
solutions and services that help support and protect the public's
health. We value the trust that our customers place in us, and
their continued efforts to improve the safety of the blood supply.
We believe that the introduction of this first module of the
ElDorado suite will accelerate growth and bring us closer to our
goal of becoming a world leader in blood management software and
services." About Global Med Technologies, Inc. Global Med
Technologies, Inc. is an international e-Health medical information
technology company providing information management software
products and services to the healthcare industry. Its Wyndgate
Technologies division is a leading supplier of information
management systems to U.S. and international blood centers and
hospital transfusion centers. Each year, Wyndgate's products and
services manage more than eight million blood components,
representing over 27% of the U.S. blood supply. Wyndgate's products
are being used in Canada and sub-Saharan Africa, and are being
implemented in the Caribbean. Together, the SafeTrace Tx(R)*
advanced transfusion management system and the SafeTrace donor
management system provide Vein-to-Vein(R) tracking from donor
collection to patient transfusion. For more information about
Global Med's products and services, please call 800-WYNDGATE or
visit http://www.globalmedtech.com/, http://www.peoplemed.com/ and
http://www.wyndgate.com/. This news release may include statements
that constitute forward-looking statements, usually containing the
words "believe," "estimate," "project," "expects" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release. *Patent Pending Company Contact: Investor
Contact: Global Med Technologies, Inc. Paul Holm Michael I. Ruxin,
M.D. H.L. Lanzet (303) 238-2000 (212) 888-4570
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies,
Inc., +1-303-238-2000; investors, Paul Holm, , or H.L. Lanzet, both
of Global Med Technologies, Inc., +1-212-888-4570 Web site:
http://www.globalmedtech.com/ http://www.peoplemed.com/
http://www.wyndgate.com/
Copyright